ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Swiss pharmaceutical services firm Lonza says it will add 11 manufacturing suites for drug spray drying, hot-melt extrusion, and melt-spray-congeal processing in Bend, Oregon. The project is scheduled for completion in 2022. Lonza also announced a collaboration with an unnamed firm in which it will build two units in Visp, Switzerland, for creating antibody-drug conjugates. And at its oral drug development and production operations in Tampa, Florida, Lonza has added equipment for processing highly potent materials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter